Horizon Therapeutics (HZNP) Tops Q2 EPS by 4c on Revenue Blowout, Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to Horizon Therapeutics (HZNP) Tops Q2 EPS by 4c on Revenue Blowout, Raises Outlook

Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EB

August 5, 2020 7:00 AM EDT

-- Record Second-Quarter 2020 Net Sales of $462.8 Million Increased 44 Percent;
Second-Quarter 2020 GAAP Net Loss of $80.0 Million; Adjusted EBITDA of $190.7 Million --

-- Quarterly Orphan Segment Net Sales Increased 87 Percent to $379.3 Million;
Now Represents More Than 80 Percent of Total Company Net Sales --

-- TEPEZZA (teprotumumab-trbw) Second-Quarter 2020 Net Sales of $165.9 Million
Driven by Strong Commercial Execution, Significantly Exceeding Expectations;
Increasing Full-Year 2020 Guidance to Greater Than $650 Million from Greater Than $200 Million --

-- Increasing TEPEZZA Peak U.S. Annual Net Sales Estimate... More